The global live biotherapeutics products and microbe CDMO market size was valued at USD 14.3 million in 2022 and is expected to grow at a compound annual growth rate (CAGR) of 41.3% from 2023 to 2030. The rising importance of the potential advantages of live biotherapeutic products (LBPs) and microbiome-based therapeutics in treating a variety of diseases, including inflammatory bowel disease, cancer, and neurological disorders, among patients and healthcare providers is the prime factor that propels market growth. Furthermore, increasing prevalence of chronic diseases and the growing demand for personalized medicine are also contributing to the expansion of the market.
CDMOs specializing in these fields have the expertise and infrastructure to support the development and manufacturing of these complex therapies, which require specialized equipment and facilities. As a result, pharmaceutical and biotech companies can outsource their production to CDMOs, allowing them to focus on research and development.
Moreover, there is a growing interest in LBPs and the microbiome as potential therapeutic agents, leading to increased research and development activities in these areas. This has resulted in a greater demand for CDMOs with expertise in these fields. Advances in sequencing technologies and bioinformatics have allowed for a deeper understanding of the microbiome and its role in health and disease. This has enabled the development of more targeted and effective live biotherapeutic products and microbiome-based therapies.
Moreover, regulatory bodies, such as the FDA, have recognized the potential of live biotherapeutic products and the microbiome and have provided guidance on the development and approval of these products. This has increased investor confidence and encouraged companies to invest in the development of these products. Overall, the LBPs and microbiome CDMO market is expected to experience significant growth in the coming years due to these drivers and the increasing interest in these innovative therapies.
The C.difficle dominated the market and held 83.6% of the market share in 2022. On the basis of application, the live biotherapeutic products and microbiome CDMO industry is segmented into C.difficle, Crohns disease, IBS, Diabetes, and Others. C. difficile is a bacterium that is found in the human gut microbiome and can cause severe diarrhea and colitis, particularly in people who have recently taken antibiotics. In recent years, there has been growing interest in using live biotherapeutic products (LBPs) to treat a range of diseases, including those related to the gut microbiome.
Live biotherapeutics products are living organisms, such as bacteria or viruses, that are used to prevent or treat diseases. C. difficile is one of the organisms that can be used as an LBP, and there has been some research into its potential use for treating C. difficile infections. As research into the human microbiome and the potential applications of LBPs continues to grow, it is likely that the market will show more interest in the use of C. difficile and other organisms for therapeutic purposes.
North America held dominant share of 79.2% in 2022, primarily due to the presence of key players and increasing investments in research and development activities in this region. The growing demand for effective treatments for various diseases such as C.difficile, Crohn's disease, and IBS, has also contributed to the market growth in North America.
Moreover, the region has a large number of established pharmaceutical and biotech companies with expertise in the development and commercialization of biologic products, including live biotherapeutic products and microbiome-based therapies. Additionally, the region has a well-established regulatory framework for biopharmaceuticals, which provides a stable environment for companies to develop and manufacture these products. Adding to it, North America has a strong research infrastructure, including top universities and research institutions, that drive innovation in the field. This has led to the development of cutting-edge technologies and techniques that are used in the production of live biotherapeutic products and microbiome-based therapies.
Market players are undertaking various strategic initiatives such as partnerships, collaborations, mergers and acquisitions, and geographic expansion, aiming to strengthen their service portfolio, and provide a competitive advantage. Some of the prominent players in the global live biotherapeutic products and microbiome CDMO market include:
Arrant Bio
4D Pharma
Cerbios
Biose Industrie
Assembly Biosciences, Inc.
Wacker Chemie AG
Quay Pharmaceuticals
NIZO
Lonza
Inpac Probiotics
Report Attribute |
Details |
Market size value in 2023 |
USD 31.8 million |
Revenue forecast in 2030 |
USD 358.0 million |
Growth rate |
CAGR of 41.3% from 2023 to 2030 |
Base year for estimation |
2022 |
Actual estimates |
2018 - 2021 |
Forecast period |
2023 - 2030 |
Quantitative units |
Revenue in USD million, and CAGR from 2023 to 2030 |
Report coverage |
Revenue forecast, company share, competitive landscape, growth factors and trends |
Segments Covered |
Application, region |
Regional scope |
North America; Europe; Asia Pacific; Latin America; MEA |
Country Scope |
U.S.; Canada; UK; Germany; France; Italy; Spain; Denmark; Sweden; Norway; Japan; China; India; Australia; South Korea; Thailand; Brazil; Mexico; Argentina; South Africa; Saudi Arabia; UAE; Kuwait |
Key companies profiled |
Arrant Bio; 4D Pharma; Cerbios; Biose Industrie; Assembly Bioscience Inc.; Wacker Chemie AG; Quay Pharmaceuticals; NIZO; Lonza; Inpac Probiotics |
Customization scope |
Free report customization (equivalent up to 8 analyst’s working days) with purchase. Addition or alteration to country, regional & segment scope. |
Pricing and purchase options |
Avail customized purchase options to meet your exact research needs. Explore purchase options |
This report forecasts revenue growth at global, regional, country levels and provides an analysis of the latest industry trends in each of the sub-segments from 2018 to 2030. For the purpose of this study, Grand View Research has segmented the global live biotherapeutic products and microbiome CDMO market report on the basis of application, and region:
Application Outlook (Revenue, USD Million, 2018 - 2030)
C.difficle
Crohns Disease
IBS
Diabetes
Others
Regional Outlook (Revenue, USD Million, 2018 - 2030)
North America
U.S.
Canada
Europe
UK
Germany
France
Italy
Spain
Denmark
Sweden
Norway
Asia Pacific
Japan
China
India
Australia
South Korea
Thailand
Latin America
Brazil
Mexico
Argentina
Middle East & Africa
South Africa
Saudi Arabia
UAE
Kuwait
b. The global live biotherapeutics products and microbiome CDMO market size was estimated at USD 14.3 million in 2022 and is expected to reach USD 31.8 million in 2030.
b. The global live biotherapeutics products and microbiome CDMO market is expected to grow at a compound annual growth rate of 41.3% from 2023 to 2030 to reach USD 358.0 million by 2030.
b. North America dominated the live biotherapeutics products and microbiome CDMO market with a share of 79.2% in 2022. This is attributable to the presence of key players and increasing investments in research and development activities in this region.
b. Arrant Bio; 4D Pharma; Cerbios; Biose Industrie; Assembly Bioscience Inc.; Wacker Chemie AG; Quay Pharmaceuticals; NIZO; Lonza; Inpac Probiotics
b. The rising importance of the potential advantages of live biotherapeutic products and microbiome-based therapeutics in treating a variety of diseases, including inflammatory bowel disease, cancer, and neurological disorders, among patients and healthcare providers is the prime factor that propels market growth
GET A FREE SAMPLE
This FREE sample includes market data points, ranging from trend analyses to market estimates & forecasts. See for yourself.
NEED A CUSTOM REPORT?
We can customize every report - free of charge - including purchasing stand-alone sections or country-level reports, as well as offer affordable discounts for start-ups & universities.
Contact us now to get our best pricing.
ESOMAR certified & member
ISO Certified
We are GDPR and CCPA compliant! Your transaction & personal information is safe and secure. For more details, please read our privacy policy.
"The quality of research they have done for us has been excellent."
We value your investment and offer free customization with every report to fulfil your exact research needs.